Treatment of visceral Leishmaniasis unresponsive to pentamidine with amphotericin B
Giri, O.P.
Journal of the Association of Physicians of India 42(9): 688-689
1994
ISSN/ISBN: 0004-5772 PMID: 7883659 Document Number: 425953
Twenty five cases of visceral leishmaniasis unresponsive to Pentamidine were treated with Amphotericin B in the dose schedule of 0.75 mg per kg body weight I.V. on alternate days for total 15 infusions. Full cure was achieved in all twenty five (hundred per cent) cases, no significant toxicity was observed during as well as after treatment and none of the patients relapsed during twelve months follow-up.
Document emailed within 1 workday
Related Documents
Singh, G.P.; Saxena, R.K.; Priyadarshy, V. 2010: Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B Journal of the Indian Medical Association 108(1): 27-28Tavil, B.ül.; Seçmeer, G.ül.; Ozen, H.; Cengiz, A.B.ül.; Unal, S.; Gürgey, A. 2008: Foamy histiocytes in a patient with visceral leishmaniasis after treatment with liposomal amphotericin B Turkish Journal of Pediatrics 50(1): 67-69
Sundar, S.; Mehta, H.; Suresh, A.V.; Singh, S.P.; Rai, M.; Murray, H.W. 2004: Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 38(3): 377-383
Giri, O.P. 1993: Amphotericin B in visceral leishmaniasis Indian Pediatrics 30(1): 74-78
Güleç, S.Geylanı.; Kizilyer, Y.; Karaman, S.; Erdem, E.; Urganci, N. 2010: Case report: the efficacy of amphotericin B in visceral leishmaniasis Turkiye Parazitolojii Dergisi 34(2): 73-75
Ashford, D.A.; Badaro, R.; Eulalio, C.; Freire, M.; Miranda, C.; Zalis, M.G.; David, J.R. 1993: Studies on the control of visceral leishmaniasis: validation of the Falcon assay screening test--enzyme-linked immunosorbent assay (FAST-ELISA) for field diagnosis of canine visceral leishmaniasis American Journal of Tropical Medicine and Hygiene 48(1): 1-8
Gelanew, T.; Hurissa, Z.; Diro, E.; Kassahun, A.; Kuhls, K.; Schönian, G.; Hailu, A. 2011: Disseminated cutaneous leishmaniasis resembling post-kala-azar dermal leishmaniasis caused by Leishmania donovani in three patients co-infected with visceral leishmaniasis and human immunodeficiency virus/acquired immunodeficiency syndrome in Ethiopia American Journal of Tropical Medicine and Hygiene 84(6): 906-912
Wali, J.P.; Sharma, S.K.; Guleria, J.S. 1984: Treatment of visceral leishmaniasis Journal of the Association of Physicians of India 32(9): 813-814
Rapp, C.; Imbert, P.; Darie, H.; Simon, F.; Gros, P.; Debord, T.; Roué, R. 2003: Liposomal amphotericin B treatment of cutaneous leishmaniasis contracted in Djibouti and resistant to meglumine antimoniate Bulletin de la Societe de Pathologie Exotique 96(3): 209-211
Pourahmad, M.; Hooshmand, F.; Rahiminejad, M. 2009: Cutaneous leishmaniasis associated with visceral leishmaniasis in a case of acquired immunodeficiency syndrome (AIDS) International Journal of Dermatology 48(1): 59-61
Peterslund, N.A.; Pallesen, G.; Bertel, L. 1982: Visceral leishmaniasis (kala-azar). Report of a case of infantile Mediterranean leishmaniasis Ugeskrift for Laeger 144(40): 2948-2949
Addadi, K.; Dedet, J.P. 1976: Epidemiology of leishmaniasis in Algeria. 6. Survey of clinical cases of infantile visceral leishmaniasis from 1965 to 1974 Bulletin de la Societe de Pathologie Exotique et de Ses Filiales 69(1): 68-75
Furtado Vieira, J.B.tista.; Evelim Coelho, G. 1998: Visceral leishmaniasis epidemiological and control aspects Leishmaniose visceral ou calazar aspectos epidemiologicos e de controle Revista da Sociedade Brasileira de Medicina Tropical 31: 85-92 (Suplemento 2
Rosenthal, E.; Marty, P. 2003: Recent understanding in the treatment of visceral leishmaniasis Journal of Postgraduate Medicine 49(1): 61-68
Laroche, R.; Sirol, J.; Poli, L. 1978: Treatment of visceral leishmaniasis or kala-azar Medecine Tropicale: Revue du Corps de Sante Colonial 38(4): 401-404
Fusai, T.; Durand, R.; Boulard, Y.; Paul, M.; Bories, C.; Rivollet, D.; Houin, R.; Deniau, M. 1995: Importance of drug carriers in the treatment of visceral leishmaniasis Medecine Tropicale: Revue du Corps de Sante Colonial 55(1): 73-78
Das, V.N.R.; Ranjan, A.; Bimal, S.; Siddique, N.A.; Pandey, K.; Kumar, N.; Verma, N.; Singh, V.P.; Sinha, P.K.; Bhattacharya, S.K. 2005: Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar National Medical Journal of India 18(3): 131-133
Murray, H.W. 2000: Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches International Journal of Infectious Diseases: Ijid: Official Publication of the International Society for Infectious Diseases 4(3): 158-177
Jha, T.K.; Sundar, S.; Thakur, C.P.; Felton, J.Mark.; Sabin, A.J.; Horton, J. 2005: A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India American Journal of Tropical Medicine and Hygiene 73(6): 1005-1011
Sinha, P.K.; Bimal, S.; Singh, S.K.; Pandey, K.; Gangopadhyay, D.N.; Bhattacharya, S.K. 2006: Pre- and post-treatment evaluation of immunological features in Indian visceral leishmaniasis (VL) patients with HIV co-infection Indian Journal of Medical Research 123(3): 197-202